Pharmaceutical

Bayer subsidiary Vividion secures rights to Werner helicase inhibitor

Vividion Therapeutics has secured worldwide rights for developing and commercialising VVD-214, the Werner helicase (WRN) covalent inhibitor.

Jun 7, 2025 - 06:00
Bayer subsidiary Vividion secures rights to Werner helicase inhibitor
Vividion Therapeutics has secured worldwide rights for developing and commercialising VVD-214, the Werner helicase (WRN) covalent inhibitor.
Read the original article

Tags:

Previous Article

‘Dupixent-fuelled’ atopic dermatitis market sales to hit $22.4bn by 2033

Next Article

MHRA warns women using weight loss jabs must use effective contraception

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

BMS licenses TCR-T immunotherapy therapy from Immatics

BMS licenses TCR-T immunotherapy therapy from Immatics

May 2, 2023

Combatting Infectious Disease: Challenges and Opportunities for Pharma in the Green Transition

Combatting Infectious Disease: Challenges and Opportuni...

Nov 29, 2024

ChatGPT doesn’t know much about drugs, Hims & Hers enters weight-loss market

ChatGPT doesn’t know much about drugs, Hims & Hers ente...

Dec 5, 2023